Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

Szydlo, 1997, Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, J Clin Oncol, 15, 1767, 10.1200/JCO.1997.15.5.1767

Anasetti, 1990, Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma, Hum Immunol, 29, 79, 10.1016/0198-8859(90)90071-V

Ash, 1991, Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion, Bone Marrow Transplant, 7, 443

Kawase, 2007, High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implications for its molecular mechanism, Blood, 110, 2235, 10.1182/blood-2007-02-072405

Kanda, 2003, Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000), Blood, 102, 1541, 10.1182/blood-2003-02-0430

Petersdorf, 1998, Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient, Blood, 92, 3515, 10.1182/blood.V92.10.3515

Morishima, 2007, Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T cell-replete marrow from an unrelated donor, Biol Blood Marrow Transplant, 13, 315, 10.1016/j.bbmt.2006.10.027

Strauss, 2002, Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs, Clin Exp Immunol, 128, 255, 10.1046/j.1365-2249.2002.01777.x

Eto, 1991, Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice, J Immunol, 146, 1402, 10.4049/jimmunol.146.5.1402

Luznik, 2002, Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation, Biol Blood Marrow Transplant, 8, 131, 10.1053/bbmt.2002.v8.pm11939602

Luznik, 2001, Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide, Blood, 98, 3456, 10.1182/blood.V98.12.3456

Mayumi, 1996, Cyclophosphamide-induced immunological tolerance: an overview, Immunobiology, 195, 129, 10.1016/S0171-2985(96)80033-7

Mayumi, 1987, Drug-induced tolerance to allografts in mice, XII: the relationships between tolerance, chimerism, and graft-versus-host disease, Transplantation, 44, 286, 10.1097/00007890-198708000-00021

Luznik, 2008, Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent for prevention of acute and chronic graft-versus-host disease after myeloablative HLA-matched related and unrelated bone marrow transplantation (BMT), Blood, 112, 28, 10.1182/blood.V112.11.56.56

O'Donnell, 2002, Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 8, 377, 10.1053/bbmt.2002.v8.pm12171484

Luznik, 2008, HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, 14, 641, 10.1016/j.bbmt.2008.03.005

Schwartz, 1959, Drug-induced immunological tolerance, Nature, 183, 1682, 10.1038/1831682a0

Burroughs, 2008, Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma, Biol Blood Marrow Transplant, 14, 1279, 10.1016/j.bbmt.2008.08.014

Przepiorka, 1995, 1994 Consensus Conference on acute GVHD grading, Bone Marrow Transplant, 15, 825

Alousi, 2009, Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network, Blood, 114, 511, 10.1182/blood-2009-03-212290

Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, I: Diagnosis and Staging Working Group report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004

Shulman, 1980, Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients, Am J Med, 69, 204, 10.1016/0002-9343(80)90380-0

Gray, 1988, A class of k-sample tests for comparing the cumulative incidence of a competing risk, Ann Stat, 16, 1141, 10.1214/aos/1176350951

Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144

Ihaka, 1996, a language for data analysis and graphics, J Comput Graph Stat, 5, 299

Kolb, 2008, Graft-versus-leukemia effects of transplantation and donor lymphocytes, Blood, 112, 4371, 10.1182/blood-2008-03-077974

Larsen, 1996, Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways, Nature, 381, 434, 10.1038/381434a0

Anderson, 2003, Memory CD4 + T cells do not induce graft-versus-host disease, J Clin Invest, 112, 101, 10.1172/JCI17601

Zheng, 2008, Effector memory CD4 + T cells mediate graft-versus-leukemia without inducing graft-versus-host disease, Blood, 111, 2476, 10.1182/blood-2007-08-109678

Kamiryo, 2009, Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor, Cancer Res, 69, 5151, 10.1158/0008-5472.CAN-08-2517

Hsu, 2006, KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy, Biol Blood Marrow Transplant, 12, 828, 10.1016/j.bbmt.2006.04.008

Ruggeri, 2007, Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value, Blood, 110, 433, 10.1182/blood-2006-07-038687

Diaconescu, 2004, Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors, Blood, 104, 1550, 10.1182/blood-2004-03-0804

Mielcarek, 2003, Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, 102, 756, 10.1182/blood-2002-08-2628

Le Blanc, 2004, A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem cell transplantation, Transplantation, 78, 1014, 10.1097/01.TP.0000129809.09718.7E

de Lima, 2004, Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation, Blood, 104, 865, 10.1182/blood-2003-11-3750

Rodriguez, 2006, Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma, Biol Blood Marrow Transplant, 12, 1326, 10.1016/j.bbmt.2006.08.035

Weng, 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J Clin Oncol, 21, 3940, 10.1200/JCO.2003.05.013